Srinivas Tejaswinhi - 02139 Cambridge, MA

Business Name: Srinivas Tejaswinhi
Categorized In: Research and Development Laboratories
Address: 852 Msschusetts Avenue Apartment 6, Cambridge, MA 02139
Phone Number: (781) 223-6085
Contact Person: Tejaswinhi Srinivas
NAICS Code: 541712
SIC Code: 8731
Business Type: B2B (Business to Business)
Founding Year: 2009
Employee #: 1 to 4
Location Type: Single Location
Annual Revenue ($): $0 to $49.999
Share This Business:
Similar Businesses: Ambri Inc - Cambridge, MA 02139
Simba Medical LLC - Cambridge, MA 02139
Sunpoint Technologies Inc - Cambridge, MA 02139
Aramark - Cambridge, MA 02139
Twin Lights Bioscience Inc - Cambridge, MA 02139
Good Start Genetics Inc - Cambridge, MA 02139
Hybrid Silica Technologies Inc - Cambridge, MA 02139
Unison Technologies LLC - Cambridge, MA 02139
H3 Biomedicine Inc - Cambridge, MA 02139
Gemedy Inc - Cambridge, MA 02139
Axios Biosciences LLC - Cambridge, MA 02139
Seaside Therapeutics LLC - Cambridge, MA 02139
Epieye Technologies - Cambridge, MA 02139
Realtime Technologies Limited - Cambridge, MA 02139
Axia Systems Technology Inc - Cambridge, MA 02139
Kozmoz LLC - Cambridge, MA 02139
Ektek LLC - Cambridge, MA 02139
Q-State Biosciences Inc - Cambridge, MA 02139
Oravax Inc - Cambridge, MA 02139
One Cell - Cambridge, MA 02139

Srinivas Tejaswinhi provides professional Research and Development Laboratories from its single location at the coordinates 42.367385,-71.107271.

The company offers B2B variables under the SIC code 8731 and NAICS code 541712, while making an annual revenue of $0 to $49.999 and hiring a total of 1 to 4 employees.

Founded in 2009, the company can now be visited at 852 Msschusetts Avenue Apartment 6, Cambridge, Massachusetts 02139 or contacted through representative Tejaswinhi Srinivas at (781) 223-6085.

For frequently asked questions and further inquiries about professional Research and Development Laboratories, get to know more about Srinivas Tejaswinhi through its company website at . Engage with this business on its social media platforms through on Twitter and on Facebook.